Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
181-200 of 2,251 trials

Advanced Cutaneous Squamous Cell Carcinoma: INCB099280 Study

We are evaluating a new medication for people with advanced cutaneous squamous cell carcinoma to see how safe it is and if it may help improve their condition.

Recurrent and Metastatic Skin Squamous Cell Carcinoma1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementDermatologyOncology

Acute Myeloid Leukemia: Gilteritinib vs. Midostaurin

We are studying whether gilteritinib works better than midostaurin for patients with AML or MDS with a FLT3 mutation. This trial looks at treatment effectiveness and safety during chemotherapy and maintenance therapy.

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome with Excess Blasts 2 (MDS-EB2)1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Beta-Thalassemia: Luspatercept for Children

We are studying a new treatment called luspatercept for children with beta-thalassemia to find a safe dose and evaluate its effects on blood health. This trial includes both transfusion-dependent and non-transfusion-dependent participants.

Beta Thalassemia>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyPediatrics

Atrial Fibrillation: Warfarin Study for Dialysis Patients

We are investigating the safety and effectiveness of warfarin in patients with atrial fibrillation who are on dialysis. This study aims to understand how this medication impacts their health.

Atrial FibrillationEnd-Stage Renal Disease>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyNephrology

Nipocalimab for Children with Generalized Myasthenia Gravis

We are studying a new treatment for children aged 2 to 17 with generalized myasthenia gravis who are not getting enough benefit from their current therapy. The trial will help us learn about its safety and effectiveness.

Myasthenia Gravis6-12 monthsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNeurologyPediatrics

Late-onset Pompe Disease: Cipaglucosidase Alfa and Miglustat Study

We are evaluating the safety and effectiveness of a new treatment for children with late-onset Pompe disease. This study aims to understand how well the medications work together and their effects on young patients.

Late-onset Pompe Disease1-2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyHematologyPediatrics

Lymphoma Treatment Study: Zanubrutinib vs. Lenalidomide

We are comparing the effectiveness of zanubrutinib combined with anti-CD20 antibodies against lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma. This study aims to find out which treatment works better and is safer.

Marginal Zone LymphomaFollicular Lymphoma>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Ovarian Cancer: NiraParib Maintenance Study

We are studying whether three cycles of chemotherapy followed by the drug niraparib is as effective as six cycles for patients with advanced ovarian cancer. This trial focuses on those who have had their tumors completely removed and are HRD-positive.

Ovarian and Fallopian Tube Cancer>2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Advanced Solid Tumors: TNG462 Treatment Study

We are testing a new treatment called TNG462 for patients with advanced solid tumors that have a specific genetic deletion. The study aims to evaluate its safety and effectiveness, both alone and with another medication.

Advanced or Metastatic Solid Tumors with MTAP Deletion>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Diffuse Large B-Cell Lymphoma: Zilovertamab Vedotin Study

We are studying a new treatment, Zilovertamab Vedotin, combined with standard care for patients with relapsed or refractory diffuse large B-cell lymphoma. The aim is to evaluate its safety and effectiveness compared to current therapies.

Diffuse Large B-Cell Lymphoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesHematologyOncology

Perianal Fistulas: Regenerative Cell Therapy Study

We are evaluating a new treatment combining surgery and regenerative cell therapy for people with complex perianal fistulas. The goal is to see if this approach improves healing outcomes.

Perianal Fistula>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGastroenterology

Non-Hodgkin Lymphoma: GLPG5101 Treatment Study

We are evaluating a new treatment called GLPG5101 for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The study aims to understand its safety and effectiveness compared to existing options.

Relapsed/Refractory B-cell Non-Hodgkin Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Relapsing Multiple Sclerosis: Rituximab vs. Ocrelizumab

We are studying whether rituximab is as effective as ocrelizumab for treating relapsing MS. This trial is for patients who are starting anti-CD20 therapy.

Multiple Sclerosis>2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNeurology

Relapsed/Refractory AML: Venetoclax and Decitabine Therapy

We are studying a new combination treatment for patients with relapsed or refractory acute myeloid leukemia. The aim is to see if this therapy can help achieve remission and improve safety and recovery outcomes.

Acute Myeloid Leukemia>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyOncology

IMC-F106C for Advanced PRAME-Positive Cancers

We are studying a new treatment called IMC-F106C for individuals with advanced PRAME-positive cancers. The trial aims to assess its safety and effectiveness, both alone and with other cancer therapies.

Urothelial CarcinomaNon-Small Cell Lung CancerOvarian Carcinoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Vulvar Carcinoma: Chemoradiation vs. Neoadjuvant Chemotherapy

We are comparing two treatment approaches for locally advanced vulvar carcinoma to see which is more effective and safe. We also want to understand how these treatments impact quality of life and the influence of HPV status.

LAVC (Locally Advanced Vulvar Cancer)>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Wilms Tumor: Metronomic Chemotherapy Study

We are evaluating a new chemotherapy regimen for children and teenagers with relapsed or refractory Wilms tumor. The study aims to assess safety, effectiveness, and quality of life during treatment.

Wilms Tumor6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Advanced Ovarian Cancer: New Chemotherapy Approach

We are investigating a combined chemotherapy treatment for patients with advanced ovarian cancer after surgery. The study aims to assess its safety, effectiveness, and impact on quality of life.

Ovarian Cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Mifepristone as a Weekly Contraceptive

We are studying the effectiveness and safety of a weekly dose of mifepristone for contraception. This trial also looks at how well patients accept this method and any potential effects on liver function.

Oral Contraception1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGynecology and Obstetrics

Neuroendocrine Tumors: SAUNA Trial on Somatostatin Analogues

We are studying whether continuing or stopping somatostatin analogues affects survival and quality of life in patients with neuroendocrine tumors after disease progression. This trial aims to provide insights into the best treatment strategies for these patients.

Neuroendocrine Tumors1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyOncology